141 related articles for article (PubMed ID: 3717976)
1. Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis.
Jones SK; Aherne GW; Campbell MJ; White JE
Arch Dermatol; 1986 Jun; 122(6):666-9. PubMed ID: 3717976
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate therapy of psoriasis. Effect and side effects with particular reference to hepatic changes. A survey.
Nyfors A
Dan Med Bull; 1980 Apr; 27(2):74-96. PubMed ID: 7000451
[No Abstract] [Full Text] [Related]
4. [Incidence of liver diseases in psoriatic patients with special reference to methotrexate therapy].
Moldenhauer E; Dabels J; Diwok K; Leithäuser W; Nowotny P
Dermatol Monatsschr; 1973 Mar; 159(3):242-8. PubMed ID: 4704945
[No Abstract] [Full Text] [Related]
5. [Oral methotrexate therapy: pro and con].
Zachariae H
Hautarzt; 1985 Jan; 36(1):10-2. PubMed ID: 3972575
[TBL] [Abstract][Full Text] [Related]
6. Systemic chemotherapy for psoriasis: a national survey.
Bergstresser PR; Schreiber SH; Weinstein GD
Arch Dermatol; 1976 Jul; 112(7):977-81. PubMed ID: 947151
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary and hepatic complications of methotrexate therapy of psoriasis.
Filip DJ; Logue GL; Harle TS; Farrar WH
JAMA; 1971 May; 216(5):881-2. PubMed ID: 5108291
[No Abstract] [Full Text] [Related]
8. Liver injury associated with methotrexate therapy for psoriasis.
Podurgiel BJ; McGill DB; Ludwig J; Taylor WF; Muller SA
Mayo Clin Proc; 1973 Nov; 48(11):787-92. PubMed ID: 4758150
[No Abstract] [Full Text] [Related]
9. Severe liver damage caused by treatment of psoriasis with methotrexate.
Pai SH; Werthamer S; Zak FG
N Y State J Med; 1973 Nov; 73(21):2585-7. PubMed ID: 4518596
[No Abstract] [Full Text] [Related]
10. Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels.
Heydendael VM; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
Arch Dermatol; 2004 Oct; 140(10):1289-90. PubMed ID: 15492205
[No Abstract] [Full Text] [Related]
11. Methotrexate induced liver disease in psoriasis.
Millward-Sadler GH; Ryan TJ
Br J Dermatol; 1974 Jun; 90(6):661-7. PubMed ID: 4853200
[No Abstract] [Full Text] [Related]
12. Hepatotoxicity of long-term methotrexate therapy for psoriasis.
Tobias H; Auerbach R
Arch Intern Med; 1973 Sep; 132(3):391-6. PubMed ID: 4783020
[No Abstract] [Full Text] [Related]
13. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.
Barker J; Horn EJ; Lebwohl M; Warren RB; Nast A; Rosenberg W; Smith C;
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):758-64. PubMed ID: 21198946
[TBL] [Abstract][Full Text] [Related]
14. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
Paramsothy J; Strange R; Sharif H; Collins M; Shaw P; Lawrence CM
Br J Dermatol; 1988 Dec; 119(6):761-5. PubMed ID: 3203069
[TBL] [Abstract][Full Text] [Related]
15. The aminopyrine breath test, an inadequate early indicator of methotrexate-induced liver disease in patients with psoriasis.
Williams CN; McCauley D; Malatjalian DA; Turnbull GK; Ross JB
Clin Invest Med; 1987 Mar; 10(2):54-8. PubMed ID: 3581546
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate hepatotoxicity and concentrations of methotrexate and folate in erythrocytes--relation to liver fibrosis and cirrhosis.
Zachariae H; Schrøder H; Foged E; Søgaard H
Acta Derm Venereol; 1987; 67(4):336-40. PubMed ID: 2445154
[TBL] [Abstract][Full Text] [Related]
17. Hazards of prolonged low-dose methotrexate therapy.
Bender AS
Va Med Mon (1918); 1970 Apr; 97(4):218-9. PubMed ID: 5317468
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of small doses of methotrexate in patients with psoriasis.
Kamel RS; al-Hakiem MH; Rademaker M; Meyrick Thomas RH; Munro DD
Acta Derm Venereol; 1988; 68(3):267-70. PubMed ID: 2455425
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate in psoriasis with and without leucovorin: effect of different dosage schedules on acute liver toxicity.
Zachariae H; Bjerring P
Acta Derm Venereol; 1982; 62(5):446-8. PubMed ID: 6183902
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis.
Weinstein GD; Cox JW; Suringa DW; Millard MM; Kalser M; Frost P
Arch Dermatol; 1970 Dec; 102(6):613-8. PubMed ID: 5501902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
